Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs Defy Medical

Two GLP-1 desks, one scoreboard. We put Sprout Health and Defy Medical head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 453 · Grade C

Defy Medical

Visit Defy Medical Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 50 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make Defy Medical a bad call — it's best for patients wanting glp-1 in injection, odt, or drop forms with thorough lab workups. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
40
Supply Reliability
82
73
Transparency
88
20
Access Breadth
92
36
Clinical Oversight
78
72
Track Record
84
70
Sprout HealthBrief Score 86 · 50Defy Medical

Price, coverage & the tracker

Sprout HealthDefy Medical
Brief Score86/100 (B)50/100 (C)
Semaglutide$149/moNot disclosed
Tirzepatide$199/moNot disclosed
CoverageNot disclosedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

Defy Medical: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.